Sign in
Active, not recruitingPhase 1

Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants

Key facts

Who runs it
BioMarin Pharmaceutical
Where
Charleston, Cincinnati, San Diego, and St Louis, United StatesSee the 4 sitesAlso in 1 other country, 3 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
6 people enrolled
Started
21 Feb 2025
Ended
19 Aug 2026
Type of study
Interventional, 2 groups
Treatments tested
  • BMN 349
  • Placebo
Record updated
6 May 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants must have confirmation of PiZZ or PiMZ genotype
  • Females and males, of any race, 18 to 75 years of age
  • Nonsmokers, defined as not using tobacco or nicotine-containing products for at least 6 months prior to Screening

Who cannot take part

  • Current or recent use of AAT augmentation therapy
  • International normalized ratio (INR) > 1.2
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels > 125 U/L
  • Participants with recent (last 3 months) diagnosis of pneumonia

Where in United States

Also in 1 other country, 3 sites

  • The Medical University of South CarolinaCharleston, United States
  • Medpace Clinical Pharmacology UnitCincinnati, United States
  • University of California San DiegoSan Diego, United States
  • Saint Louis UniversitySt Louis, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.

Read full original descriptionShow less

Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters.

Participants will receive a single dose of either BMN 349 or placebo and then monitored for safety and tolerability.

The 2 groups in the trial

  • Group A (PiZZ)Other group

    5:1 (349:Placebo)

    Treatment: BMN 349 and Placebo

  • Group B (PiMZ)Other group

    5:1 (349:Placebo)

    Treatment: BMN 349 and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)
Record updated
6 May 2026